Product on sale

Kapvay (clonidine ER — non-stimulant)

Original price was: $135.Current price is: $132.30.

7 products sold in last 8 hours
Selling fast! Over 7 people have in their cart

Kapvay is an extended-release formulation of clonidine hydrochloride, a non-stimulant medication used to treat ADHD in children and adolescents (ages 6–17). Originally developed to treat high blood pressure, it belongs to a class of drugs called centrally acting alpha2-adrenergic agonists. In the context of ADHD, it is unique because it can be used either as a monotherapy (stand-alone treatment) or as an adjunctive therapy (add-on) to stimulant medications to help manage symptoms that stimulants may not fully address.

29 people are viewing this right now
  • Check Mark Estimated Delivery : Up to 4 business days
  • Check Mark Free Shipping & Returns : On all orders over $200
  • Visa Card
  • MasterCard
  • American Express
  • Discover Card
  • PayPal
  • Apple Pay
Guaranteed Safe And Secure Checkout

Kapvay Clonidine ER

Kapvay is a prescription medicine supplied as an extended-release tablet and is used to treat attention deficit hyperactivity disorder (ADHD).

Your doctor may prescribe Kapvay alone or together with certain other ADHD medicines.

What Are Side Effects of Kapvay?

Kapvay may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • fainting,
  • slow or irregular hearbeat,
  • mood changes,
  • irritability,
  • depression, and
  • severe dizziness

Get medical help right away, if you have any of the symptoms listed above.

Common side effects of Kapvay include:

  • drowsiness,
  • headache,
  • fatigue,
  • upper respiratory tract infection,
  • irritability,
  • anxiety,
  • sore throat,
  • dizziness,
  • insomnia,
  • nightmares,
  • emotional disorder,
  • constipation,
  • diarrhea,
  • abdominal pain,
  • nausea,
  • nasal congestion,
  • asthma,
  • increased body temperature,
  • dry mouth,
  • thirst,
  • tremor,
  • ear pain,
  • daytime urinary frequency,
  • bed wetting,
  • aggression,
  • tearfulness,
  • slow heart rate,
  • increased heart rate, and
  • decreased appetite.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Kapvay

The dose of Kapvay is individualized according to the needs and response of the patient. Dosing is initiated with one 0.1 mg tablet at bedtime, and the daily dosage is adjusted in increments of 0.1 mg/day at weekly intervals until the desired response is achieved.

What Drugs, Substances, or Supplements Interact with Kapvay?

Kapvay may interact with alcohol, barbiturates or other sedating drugs, antidepressants, digitalis, calcium channel blockers, beta-blockers, other products containing clonidine, or antihypertensive drugs. Tell your doctor all medications and supplements you use.

Kapvay During Pregnancy and Breastfeeding

During pregnancy, Kapvay should be used only if prescribed. This drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Kapvay (clonidine hydrochloride) extended-release Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

Reviews

There are no reviews yet.

Be the first to review “Kapvay (clonidine ER — non-stimulant)”

Your email address will not be published. Required fields are marked *